MOTS-c vs SS-31: Two Mitochondrial Research Peptides Compared

Research Use Only. The compounds discussed here are laboratory reagents supplied strictly for in vitro and preclinical research. They are not medicines, not supplements, and not for human or veterinary use. Nothing in this article describes or suggests any form of administration to people or animals.

MOTS-c and SS-31 are both frequently described as "mitochondrial peptides", and they often appear side by side in laboratory catalogues and in reading lists on mitochondrial biology. That shared label hides how different the two molecules actually are. One is a peptide encoded inside the mitochondrial genome itself and studied mainly as a signalling molecule. The other is a synthetic tetrapeptide designed in a medicinal chemistry programme and studied mainly for how it binds to a specific membrane lipid. This article compares the two in a research context: origin, chemistry, the preclinical literature around each, and what the practical differences mean for laboratory handling.

What is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid peptide encoded by a short open reading frame located inside the 12S ribosomal RNA region of mitochondrial DNA, which places it in the small family of mitochondrial-derived peptides alongside humanin. It was first reported in 2015 by Lee and colleagues at the University of Southern California, in the same body of work that established mitochondria as a source of signalling peptides rather than purely as metabolic organelles.

The defining feature of MOTS-c in the literature is that it is described as an endogenous, genome-encoded signal. Published work reports that under metabolic stress the peptide can relocate to the nucleus and associate with stress-responsive transcription factors, which is why it is often framed as a retrograde signal running from mitochondrion to nucleus.

What is SS-31?

SS-31, also known as elamipretide and by the earlier designation MTP-131, is a synthetic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. It belongs to the Szeto-Schiller (SS) series of aromatic-cationic peptides developed at Weill Cornell. Unlike MOTS-c it is not encoded anywhere in the genome. It is a designed molecule, and its alternating cationic and aromatic residue pattern is what allows it to concentrate in the inner mitochondrial membrane without depending on membrane potential.

Where MOTS-c is studied as a signal, SS-31 is studied as a membrane-interacting agent. Published research reports that it binds with high affinity to cardiolipin, the anionic phospholipid that is largely restricted to the inner mitochondrial membrane and that is required for normal cristae architecture.

Where they sit in the research literature

Both compounds have accumulated a substantial preclinical record, but the two literatures ask different questions. MOTS-c work is dominated by metabolic and exercise physiology models. SS-31 work is dominated by ischemia-reperfusion, cristae structure and bioenergetic recovery models.

Reported preclinical areas for MOTS-c

• Studies in cell culture have examined MOTS-c interference with the folate cycle and with de novo purine biosynthesis, with downstream activation of AMP-activated protein kinase (AMPK) reported as the proximate cellular consequence.
• Rodent models have examined skeletal muscle as the apparent primary target tissue, including reported effects on glucose handling in muscle preparations.
• Animal work has examined MOTS-c in the context of diet-induced and age-associated insulin resistance in mice.
• Observational research has examined circulating MOTS-c concentrations across age groups, with published reports describing a decline with age.
• Review literature has surveyed MOTS-c across cardiovascular, inflammatory and ageing models, while noting that no clinical application has been established.

Reported preclinical areas for SS-31

• Fluorescent-analogue binding studies have characterised the interaction between SS-31 and cardiolipin on the inner mitochondrial membrane.
• Rat models of renal ischemia have examined cristae membrane integrity and mitochondrial swelling following ischemic insult.
• Biochemical work has examined the SS-31 and cardiolipin complex in relation to cytochrome c peroxidase activity and cardiolipin peroxidation.
• Cross-linking mass spectrometry work has mapped the mitochondrial protein interaction landscape of SS-31, reporting interactors clustered around oxidative phosphorylation and 2-oxoglutarate metabolism.
• Ageing and cardiac models in rodents have been used to examine bioenergetic parameters, and the compound has been the subject of registered clinical investigation programmes in mitochondrial disease.

Chemistry and notes at a glance

MOTS-c

• Class: mitochondrial-derived peptide (MDP), genome encoded
• Length: 16 amino acids
• Sequence: MRWQEMGYIFYPRKLR
• Origin: short open reading frame within mitochondrial 12S rRNA
• Reported proximate mechanism in the literature: folate cycle and purine biosynthesis interference leading to AMPK activation
• Typical laboratory form: lyophilized powder

SS-31 (elamipretide)

• Class: synthetic aromatic-cationic tetrapeptide (Szeto-Schiller series)
• Length: 4 amino acids, C-terminal amide
• Sequence: D-Arg-2,6-dimethylTyr-Lys-Phe-NH2
• Origin: designed compound, no genomic counterpart
• Reported proximate mechanism in the literature: high-affinity binding to cardiolipin in the inner mitochondrial membrane
• Typical laboratory form: lyophilized powder

The practical contrast

A useful way to hold the difference is that the two peptides are studied at different levels of the same organelle. MOTS-c is investigated as information: a peptide that leaves the mitochondrion and changes what the nucleus does. SS-31 is investigated as structure: a peptide that stays in the inner membrane and changes the local lipid and protein environment. A comparison study that treats them as interchangeable "mitochondrial peptides" is likely to be measuring two unrelated things.

There is also a large size and stability difference. A 16-mer and a 4-mer behave differently in solution, in mass spectrometry identity work, and in handling. The shorter, heavily modified SS-31 sequence includes non-standard residues (D-arginine and a dimethylated tyrosine), which matters when planning analytical confirmation.

Why the "research use only" label matters

Neither MOTS-c nor SS-31 is an approved medicine in the European Union. Elamipretide has been the subject of registered clinical trial programmes in mitochondrial disease, which means it has been studied in humans under regulated conditions, but a compound in trials is not an approved product and material sold as a research reagent is not clinical-grade material and carries no marketing authorisation. MOTS-c has not progressed to any comparable approval status anywhere.

Under EU law the distinction is a legal one, not a formality. Research chemicals are supplied as laboratory reagents under REACH. The moment a supplier presents such a material with a health claim or with any implication of human or veterinary use, it falls under Directive 2001/83/EC as an unauthorised medicinal product. That is why every page on this site describes only what has been reported in preclinical literature, in the third person, and never describes use in a person.

A practical note on documentation: because neither peptide has a pharmacopoeial monograph, the certificate of analysis is the only meaningful evidence of what is in the vial. Our guide to peptide purity and the certificate of analysis covers what HPLC purity, peptide content and mass spectrometry identity each tell you, and why the three are not interchangeable.

Handling and storage for researchers

Both compounds are supplied as lyophilized powder and follow the general handling logic that applies to research peptides in the laboratory.

• Store lyophilized material cold and dry, protected from light, in the sealed vial as received. Long-term storage below minus 18 degrees Celsius is the usual laboratory practice for lyophilized peptides.
• Allow vials to equilibrate to room temperature before opening. Opening a cold vial in humid air draws moisture onto the powder, and hygroscopic uptake is one of the commonest sources of unexplained potency loss in peptide work.
• Reconstitute with a solvent appropriate to the peptide and the assay. Choice of solvent affects both solubility and stability, and our comparison of bacteriostatic water versus acetic acid for reconstitution sets out the trade-offs.
• Aliquot after reconstitution. Repeated freeze-thaw cycles are a documented degradation route for peptides in solution, and single-use aliquots remove the problem at the cost of a few extra tubes.
• Record lot numbers and reconstitution dates. Solution-phase stability is measured in weeks at refrigerator temperature for most peptides, not months, and undated stock is a frequent source of irreproducible results. Our peptide storage and stability guide goes into the detail.

These are laboratory reagent handling notes. They are not instructions for preparing anything for administration to a person or an animal.

Frequently asked questions

Are MOTS-c and SS-31 the same class of compound?

No. MOTS-c is a naturally encoded 16-amino-acid peptide produced from a short open reading frame in mitochondrial DNA. SS-31 is a synthetic four-residue peptide from a medicinal chemistry series, containing non-standard residues that do not occur in genomically encoded proteins. They share a research field, not a chemical class.

Is either compound approved as a medicine?

Neither is an approved medicine in the EU. Elamipretide (SS-31) has been investigated in registered clinical trials for mitochondrial disease, but investigational status is not approval. MOTS-c remains a preclinical research subject. Material supplied for research is laboratory reagent grade and is not intended, tested or authorised for any clinical purpose.

Is it legal to buy MOTS-c or SS-31 for research in the EU?

Research chemicals of this type are generally supplied within the EU as laboratory reagents under the REACH framework, provided they are sold, labelled and described strictly for research purposes and without any therapeutic claim. National rules and institutional requirements vary, so buyers are responsible for confirming the position in their own jurisdiction and at their own institution before ordering.

Which one has the larger published literature?

SS-31 and elamipretide together have the longer publication history, going back to the aromatic-cationic peptide work of the 2000s and including clinical-stage investigation. MOTS-c is newer, first reported in 2015, but the field has grown quickly and now includes several hundred indexed papers. Both are best approached through review articles first, since primary papers in each field use very different model systems.

Do the two peptides need different storage conditions?

The general principles are the same for both: cold, dry, dark, sealed, aliquoted after reconstitution. Specific solubility and solvent compatibility differ between a 16-mer and a modified tetrapeptide, so the supplier's certificate of analysis and any accompanying solubility notes should guide solvent choice for each material individually rather than applying one protocol to both.

Key takeaways

• MOTS-c is a genome-encoded 16-amino-acid mitochondrial-derived peptide studied mainly as a metabolic signalling molecule, with AMPK activation reported as its proximate cellular consequence.
• SS-31 (elamipretide) is a synthetic aromatic-cationic tetrapeptide studied mainly for high-affinity cardiolipin binding and its effects on inner membrane and cristae integrity in preclinical models.
• The shared "mitochondrial peptide" label is misleading: one is investigated as a signal to the nucleus, the other as a structural interaction inside the membrane.
• Neither is an approved medicine in the EU. Elamipretide has been in clinical investigation; MOTS-c has not.
• Both ship as lyophilized powder and follow standard research peptide handling: cold, dry, dark, aliquot after reconstitution, document everything.

Pure Chems supplies MOTS-c as a research reagent with a certificate of analysis, and further mitochondrial research materials including SS-31 can be found in our full research catalogue. For the wider context, see our overview of mitochondrial-derived peptides, and the individual compound articles on MOTS-c and SS-31 (elamipretide).

References

References sourced via PubMed.

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. DOI: 10.1016/j.cmet.2015.02.009 · PubMed 25738459
2. Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1120533 · PubMed 36761202
3. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 2013. DOI: 10.1681/ASN.2012121216 · PubMed 23813215
4. Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences, 2020. DOI: 10.1073/pnas.2002250117 · PubMed 32554501

Research Use Only. MOTS-c and SS-31 are supplied strictly as laboratory reagents for in vitro and preclinical research by qualified professionals. They are not approved medicines, not dietary supplements and not for human or veterinary use, consumption or administration. This article summarises published preclinical literature for informational purposes and does not constitute medical, scientific or legal advice.